CEREVEL THERAPEUTICS HOLDINGS, INC. Increase (Decrease) in Accounts Payable and Other Operating Liabilities
CEREVEL THERAPEUTICS HOLDINGS, INC. reported Increase (Decrease) in Accounts Payable and Other Operating Liabilities of $8.67 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities · last filed 2022-03-01
- CEREVEL THERAPEUTICS HOLDINGS, INC. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2021-12-31 was $5.87M, a 194.63% increase year-over-year.
- CEREVEL THERAPEUTICS HOLDINGS, INC. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2021-09-30 was $1.48M, a 82.96% decline year-over-year.
- CEREVEL THERAPEUTICS HOLDINGS, INC. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2021-06-30 was -$650.00K.
- CEREVEL THERAPEUTICS HOLDINGS, INC. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2021-03-31 was $1.98M, a 462.68% increase year-over-year.
- CEREVEL THERAPEUTICS HOLDINGS, INC. increase (decrease) in accounts payable and other operating liabilities for fiscal 2021 was $8.67M, a 18.88% decline from fiscal 2020.
- CEREVEL THERAPEUTICS HOLDINGS, INC. increase (decrease) in accounts payable and other operating liabilities for fiscal 2020 was $10.69M, a 35.01% increase from fiscal 2019.
- CEREVEL THERAPEUTICS HOLDINGS, INC. increase (decrease) in accounts payable and other operating liabilities for fiscal 2019 was $7.92M.
| Period end | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 3 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 6 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 9 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2021-12-31 | $5.87M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $7.35M derived: sum of 2 quarters · filed 2022-03-01 | $6.70M derived: sum of 3 quarters · filed 2022-03-01 | $8.67M 10-K · filed 2022-03-01 |
| 2021-09-30 | $1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $831.00K derived: sum of 2 quarters · filed 2021-11-10 | $2.81M 10-Q · filed 2021-11-10 | $4.80M derived: sum of 4 quarters · filed 2022-03-01 |
| 2021-06-30 | -$650.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $1.32M 10-Q · filed 2021-08-11 | $3.32M derived: sum of 3 quarters · filed 2022-03-01 | $12.01M derived: sum of 4 quarters · filed 2022-03-01 |
| 2021-03-31 | $1.98M 10-Q · filed 2021-05-17 | $3.97M derived: sum of 2 quarters · filed 2022-03-01 | $12.66M derived: sum of 3 quarters · filed 2022-03-01 | $12.31M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $10.68M derived: sum of 2 quarters · filed 2022-03-01 | $10.34M derived: sum of 3 quarters · filed 2022-03-01 | $10.69M 10-K · filed 2022-03-01 |
| 2020-09-30 | $8.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $8.35M derived: sum of 2 quarters · filed 2021-11-10 | $8.70M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$343.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $8.00K 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | $351.00K 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | $7.92M 10-K · filed 2022-03-01 |